{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T04:43:02Z","timestamp":1665549782482},"reference-count":30,"publisher":"Japanese Pharmacological Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacol Sci"],"published-print":{"date-parts":[[2013]]},"DOI":"10.1254\/jphs.13086fp","type":"journal-article","created":{"date-parts":[[2013,9,3]],"date-time":"2013-09-03T23:02:54Z","timestamp":1378249374000},"page":"58-66","source":"Crossref","is-referenced-by-count":9,"title":["Tolvaptan Attenuates Left Ventricular Fibrosis After Acute Myocardial Infarction in Rats"],"prefix":"10.1254","volume":"123","author":[{"given":"Takanori","family":"Yamazaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Shiota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayuko","family":"Osada-Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Fujiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihisa","family":"Hanatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenei","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Yoshiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Iwao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasukatsu","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"332","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81:1161\u20131172.","DOI":"10.1161\/01.CIR.81.4.1161"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101:2981\u20132988.","DOI":"10.1161\/01.CIR.101.25.2981"},{"key":"3","unstructured":"3 Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther. 2000;292:288\u2013294."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203\u2013210.","DOI":"10.1161\/01.CIR.102.2.203"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Costello-Boerrigter LC, Boerrigter G, Cataliotti A, Harty GJ, Burnett JC Jr. Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure. Circ Heart Fail. 2010;3:412\u2013419.","DOI":"10.1161\/CIRCHEARTFAILURE.109.916114"},{"key":"6","unstructured":"6 Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860\u2013867."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Broqvist M, Dahlstrom U, Karlberg BE, Karlsson E, Marklund T. Neuroendocrine response in acute heart failure and the influence of treatment. Eur Heart J. 1989;10:1075\u20131083.","DOI":"10.1093\/oxfordjournals.eurheartj.a059429"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005;46:1785\u20131791.","DOI":"10.1016\/j.jacc.2005.02.095"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Lee CR, Watkins ML, Patterson JH, Gattis W, O\u2019Connor CM, Gheorghiade M, et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J. 2003;146:9\u201318.","DOI":"10.1016\/S0002-8703(02)94708-3"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr. Pharmacology of vasopressin antagonists. Heart Fail Rev. 2009;14:75\u201382.","DOI":"10.1007\/s10741-008-9108-8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332\u20131343.","DOI":"10.1001\/jama.297.12.1332"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319\u20131331.","DOI":"10.1001\/jama.297.12.1319"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Pang PS, Konstam MA, Krasa HB, Swedberg K, Zannad F, Blair JE, et al. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J. 2009;30:2233\u20132240.","DOI":"10.1093\/eurheartj\/ehp253"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Yamazaki T, Izumi Y, Nakamura Y, Yamashita N, Fujiki H, Osada-Oka M, et al. Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats. Circ Heart Fail. 2012;5:794\u2013802.","DOI":"10.1161\/CIRCHEARTFAILURE.112.968750"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Yamazaki T, Izumi Y, Nakamura Y, Hanatani A, Shimada K, Muro T, et al. Novel device that produces carbon dioxide mist for myocardial infarction treatment in rats. Circ J. 2012;76:1203\u20131212.","DOI":"10.1253\/circj.CJ-11-1116"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Miyazaki T, Sakamoto Y, Yamashita T, Ohmoto K, Fujiki H. Anti-edematous effects of tolvaptan in experimental rodent models. Cardiovasc Drugs Ther. 2011;25 Suppl 1:S77\u2013S82.","DOI":"10.1007\/s10557-011-6355-z"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Yamazaki T, Yamashita N, Izumi Y, Nakamura Y, Shiota M, Hanatani A, et al. The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice. Hypertens Res. 2012;35:34\u201340.","DOI":"10.1038\/hr.2011.139"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Samukawa K, Izumi Y, Shiota M, Nakao T, Osada-Oka M, Miura K, et al. Red ginseng inhibits scratching behavior associated with atopic dermatitis in experimental animal models. J Pharmacol Sci. 2012;118:391\u2013400.","DOI":"10.1254\/jphs.11182FP"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Larsen FF. Haemodynamic effects of high or low doses of furosemide in acute myocardial infarction. Eur Heart J. 1988;9:125\u2013131.","DOI":"10.1093\/oxfordjournals.eurheartj.a062465"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol. 2007;49:2151\u20132159.","DOI":"10.1016\/j.jacc.2007.01.091"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52:1540\u20131545.","DOI":"10.1016\/j.jacc.2008.08.013"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Marti C, Cole R, Kalogeropoulos A, Georgiopoulou V, Butler J. Medical therapy for acute decompensated heart failure: what recent clinical trials have taught us about diuretics and vasodilators. Curr Heart Fail Rep. 2012;9:1\u20137.","DOI":"10.1007\/s11897-011-0072-6"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331:1286\u20131292.","DOI":"10.1056\/NEJM199411103311907"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Kim-Mitsuyama S, Izumi Y, Izumiya Y, Yoshida K, Yoshiyama M, Iwao H. Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model. Hypertens Res. 2004;27:771\u2013779.","DOI":"10.1291\/hypres.27.771"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63:423\u2013432.","DOI":"10.1016\/j.cardiores.2004.04.030"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Morooka H, Iwanaga Y, Tamaki Y, Takase T, Akahoshi Y, Nakano Y, et al. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure. Circ Heart Fail. 2012;5:484\u2013492.","DOI":"10.1161\/CIRCHEARTFAILURE.111.965392"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Onogawa T, Sakamoto Y, Nakamura S, Nakayama S, Fujiki H, Yamamura Y. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure. Cardiovasc Drugs Ther. 2011;25 Suppl 1:S67\u2013S76.","DOI":"10.1007\/s10557-011-6350-4"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Kodama M, et al. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Biochem Pharmacol. 2008;75:1322\u20131330.","DOI":"10.1016\/j.bcp.2007.11.011"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Balanescu S, Kopp P, Gaskill MB, Morgenthaler NG, Schindler C, Rutishauser J. Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar States. J Clin Endocrinol Metab. 2011;96:1046\u20131052.","DOI":"10.1210\/jc.2010-2499"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Morgenthaler NG. Copeptin: a biomarker of cardiovascular and renal function. Congest Heart Fail. 2010;16 Suppl 1:S37\u2013S44.","DOI":"10.1111\/j.1751-7133.2010.00177.x"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jphs\/123\/1\/123_13086FP\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T15:10:35Z","timestamp":1621437035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jphs\/123\/1\/123_13086FP\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1254\/jphs.13086fp","relation":{},"ISSN":["1347-8613","1347-8648"],"issn-type":[{"value":"1347-8613","type":"print"},{"value":"1347-8648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}